Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International journal of hematology

• Publication date

  2014-07-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12185-014-1629-4PMID 25052874
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

  2013cited by this paper
• A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group

  2013cited by this paper
• Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?

  2012cited by this paper
• Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies

  2012cited by this paper
• Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.

  2011cited by this paper
• Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B‐cell non‐Hodgkin lymphoma: 7‐year follow‐up results

  2010cited by this paper
• Phase II/III Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab (R-CHOP) Versus Biweekly CHOP with Rituximab (R-Bi-CHOP) In Untreated Advanced-Stage Indolent B-Cell Lymphoma: Japan Clinical Oncology Group (JCOG) 0203 Trial

  2010cited by this paper
• Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

  2009cited by this paper
• Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.

  2009cited by this paper
• Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab.

  2009cited by this paper
• Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study.

  2009cited by this paper
• High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.

  2009cited by this paper
• Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.

  2008cited by this paper
• Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

  2008cited by this paper
• [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].

  2008cited by this paper
• Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

  2008cited by this paper
• Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma

  2008cited by this paper
• Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

  2008cited by this paper
• Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.

  2008cited by this paper
• Follicular lymphoma international prognostic index

  2006cited by this paper
• Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t

  2005cited by this paper
• Improved survival of follicular lymphoma patients in the United States.

  2005cited by this paper
• Follicular lymphoma international prognostic index.

  2004cited by this paper
• Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

  2004cited by this paper
• Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

  2001cited by this paper
• Assessment of Prognostic Factors in Follicular Lymphoma Patients

  2001cited by this paper
• The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists.

  2000cited by this paper
• Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.

  1999cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

  1997cited by this paper
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

  1997cited by this paper
• [Prognostic factors of follicular lymphoma treated with combination chemotherapy].

  1997cited by this paper
• A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project

  1997cited by this paper
• Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan.

  1996cited by this paper
• Long-term survival after histologic transformation of low-grade follicular lymphoma.

  1995cited by this paper
• [Follicular lymphoma in Japan: retrospective study on natural history and therapeutic results in 50 cases collected from 4 institutions].

  1989cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Histologic progression in non-Hodgkin's lymphoma.

  1982cited by this paper

• Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study.

  2020cites this paper
• Incidence of solid cancer in patients with follicular lymphoma

  2019cites this paper
• Burden of illness of follicular lymphoma and marginal zone lymphoma

  2018cites this paper
• BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma

  2018influential citation
• Oxidative stress in diffuse large B-cell lymphoma and follicular lymphoma, and TP53 mutations and translocations of MYC, Bcl-2 and Bcl-6 in diffuse large B-cell lymphoma

  2018cites this paper
• Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

  2017cites this paper
• Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population‐based Study

  2017cites this paper
• Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial

  2017cites this paper
• Long‐term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90‐yttrium‐ibritumomab‐tiuxetan

  2016cites this paper